Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07336940 · ClinicalTrials.gov registry record · Phase 1
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis (AD), sponsored by Enveda Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 5
- Study locations
NCT07336940: Active Phase 1 study of Atopic Dermatitis (AD), sponsored by Enveda Therapeutics.
NCT07336940 is a Phase 1 study of Atopic Dermatitis (AD) that is active but no longer recruiting, run by Enveda Therapeutics. The registered enrollment target is 16 participants, below the 108-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (85% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07336940, a Phase 1 study of Atopic Dermatitis (AD), is active but no longer recruiting, sponsored by Enveda Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms. The main questions it will answer are: * Is ENV-294 safe and well tolerated in adults with moderate to severe atopic dermatitis? * Is there an impact on the severity of atopic dermatitis symptoms when participants take ENV-294? Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study. Participants will: * Take drug ENV-294 once every day for 28 days * Visit the clinic weekly for 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug ENV-294
Primary Outcome
Incidence and severity of adverse events, serious adverse events and adverse events leading to the discontinuation of treatment.
Conditions Studied
Interventions
- DRUG ENV-294 Capsule
Study Locations (5)
Texas
- J & S Studies - College Station
- Texas Dermatology and Laser Specialists - San Antonio
California
- Center for Dermatology Clinical Research, Inc. - Fremont
Kentucky
- Skin Sciences, PLLC - Louisville
Virginia
- Virginia Dermatology & Skin Cancer Center - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT07336940 still lists
NCT07336940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 108-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 1 intervention - of which ENV-294 Capsule is the first listed.
NCT07336940 lists 5 locations in 4 states (Texas, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT07336940 about?
NCT07336940 is a clinical study titled "Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis". The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms. The main questions it will answer are: * Is ENV-294 safe...
What is the current status of trial NCT07336940?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-09-10. Estimated completion is 2026-03.
What conditions does trial NCT07336940 study?
This clinical trial studies the following conditions: Atopic Dermatitis (AD).
What interventions are being tested in trial NCT07336940?
The interventions under investigation include: ENV-294 Capsule (DRUG).
Who is sponsoring clinical trial NCT07336940?
This trial is sponsored by Enveda Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07336940 being conducted?
This trial has 5 study locations across California, Kentucky, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
RECRUITING · Phase 1
-
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
RECRUITING · Phase 1
-
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
RECRUITING · Phase 1
-
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
ACTIVE NOT RECRUITING · Phase 1
-
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI